Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Presentation outline
- Toxicogenomics - what is it? (1)
- Toxicogenomics - what is it? (2)
- Toxicogenomics - what is it not?
- Toxicogenomics - general considerations
- Impact to screening and lead optimization
- Compound discrimination: consider via dose
- Discrimination for compounds/doses
- Molecules discrimination requires reproducibility
- Matched similarity of benchmark and compound
- Correlation with "informative" signatures
- Pathway analysis of increased genes
- Pathway modeling
- Modulation of the notch pathway
- Change in notch pathway genes after treatment
- Number of altered transcripts as an index
- Value of overall detection of transcript changes
- Understanding compound mechanism of action
- Case study
- 4-day rat studies: induced ALT and AST levels
- Differential regulation across compounds
- 28 gene signature correlates with toxicity
- Clinical candidate indicated on ALT/AST chart
- 28 gene signature of clinical candidate
- Future candidate selection
- For the future: translation
- Conclusions
- Acknowledgements
Topics Covered
- What is toxicogenomics and what is it not?
- General considerations
- Compound discrimination
- Pathway modeling
- Modulation of the notch pathway
- Altered transcripts
- Understand compound mechanism of action
- Case study: hepatotoxicity
- For the future: translation
Links
Series:
Categories:
Talk Citation
Afshari, C. (2009, August 9). Introduction to toxicogenomics and example case studies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 13, 2024, from https://doi.org/10.69645/QWHS3994.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Cindy Afshari has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.